mycophenolate sodium + valsartan

Mycophenolate sodium + valsartan is a combination of two pharmaceutical agents used primarily in transplant medicine and cardiovascular disease management. Mycophenolate sodium is an immunosuppressant that acts as a selective, reversible inhibitor of inosine monophosphate dehydrogenase, thereby inhibiting the proliferation of T and B lymphocytes and suppressing cell-mediated immune responses[2][6]. It is mainly indicated for the prevention of organ rejection in kidney, heart, or liver transplant recipients. Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the angiotensin II receptor type 1 (AT1R), leading to vasodilation, reduced aldosterone secretion, decreased cardiac activity, and increased excretion of sodium[4][1]. Valsartan is indicated for hypertension management and heart failure. The combination may be considered in patients with comorbidities requiring both immunosuppression (e.g., post-transplant) and blood pressure control.

Other names

mycophenolic acid sodiumangiotensin II receptor blocker combination